Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GSK3640254 on Cardiac Conduction (QTc) in Healthy Adults
NCT04563845Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fipravirimat in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Time t at Day 7, Area Under the Curve From Time Zero to the End of the Dosing Interval at Steady State at Day 7 and 4 more. Started Nov 2020; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04563845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563845.